Karen S. Kolba

TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.

TL;DR: In patients whose active RA persists despite treatment with MTX, tacrolimus in combination withMTX is safe and well-tolerated and provides clinical benefit.

TL;DR: The within-trial analysis and lifetime analysis found that etanercept-methotrexate as first-line therapy provided marginally more QALYs but accumulated substantially higher drug costs, and Initiating biologic therapy without trying triple therapy first increases costs while providing minimal incremental benefit.

TL;DR: This trial demonstrated a dose response relationship for meloxicam 7.5, 15, and 22.5 mg using AUC measurement of response for the treatment of RA.

TL;DR: This list is a pediatric rheumatology Top 5 list as part of the American Board of Internal Medicine Foundation's Choosing Wisely campaign.